ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

ClinicalTrials.gov ID: NCT01128530

Public ClinicalTrials.gov record NCT01128530. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Controlled, Double-Blind, Double Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection

Study identification

NCT ID
NCT01128530
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Enrollment
161 participants

Conditions and interventions

Interventions

  • JNJ-32729463 Drug
  • JNJ-32729463 placebo Drug
  • linezolid Drug
  • linezolid placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Nov 30, 2010
Completion
Dec 31, 2010
Last update posted
Dec 15, 2011

2010 – 2011

United States locations

U.S. sites
27
U.S. states
11
U.S. cities
26
Facility City State ZIP Site status
Furiex Research Site Anaheim California 92804
Furiex Research Site Buena Park California 90620
Furiex Research Site Chula Vista California 91911
Furiex Research Site Fountain Valley California 92708
Furiex Research Site La Mesa California 91942
Furiex Research Site Long Beach California 90813
Furiex Research Site Oceanside California 92056
Furiex Research Site Santa Ana California 92701
Furiex Research Site Fort Myers Florida 33912
Furiex Research Site Kissimmee Florida 34741
Furiex Research Site Saint Cloud Florida 34769
Furiex Research Site Columbus Georgia 31904
Furiex Research Site Savannah Georgia 31406
Furiex Research Site Idaho Falls Idaho 83404
Furiex Research Site Libertyville Illinois 60048
Furiex Research Site Baton Rouge Louisiana 70809
Furiex Research Site New Orleans Louisiana 70112
Furiex Research Site Sulphur Louisiana 70663
Furiex Research Site Detroit Michigan 48202
Furiex Research Site Keego Harbor Michigan 48320
Furiex Research Site Butte Montana 59701
Furiex Research Site Toledo Ohio 43608
Furiex Research Site Philadelphia Pennsylvania 19107
Furiex Research Site Houston Texas 77002
Furiex Research Site Houston Texas 77005
Furiex Research Site Sugar Land Texas 77498
Furiex Research Site Webster Texas 77598

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01128530, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 15, 2011 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01128530 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →